Background and objective: To examine the macula in preterm infants treated with bevacizumab (Avastin; Genentech, South San Francisco, CA) for retinopathy of prematurity (ROP) using spectral domain optical coherence tomography (SD-OCT).
Patients and methods: Twenty eyes (of 11 patients) treated with Avastin only or in addition to photocoagulation and vitreous surgery were included. Imaging was performed with a portable spectral-domain optical coherence tomography (OCT) device. Macular measurements, including the foveal and parafoveal index were calculated. RetCam (Clarity Medical Systems, Pleasanton, CA) photographs were obtained for all patients.
Results: Mean age of patients at OCT examination was 28.9 months (range: 4 to 50 months). Thirteen eyes (65%) developed foveal contour (FC), and seven eyes (35%) did not. Earlier gestational age and zone I disease were associated with absence of FC development. In patients without FC, two of the five eyes had vision better than 20/400, compared with 10 of 11 eyes with FC.
Conclusion: Vision tends to be better in Avastin-treated eyes when an FC is present. Morphological characteristics of retinal anatomy may predict visual function.
Dorta P, Kychenthal A. Spectral-domain optical coherence tomography of the macula in preterm infants treated with bevacizumab for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2015;46(3):321-6.